Background: Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized
by thrombosis, pregnancy morbidity, and the presence of characteristic antibodies. Current …

The purpose of this communication is to provide a brief update of our observations to date
that have led to substantive modifications to the study protocol we reported previously in …

Thrombotic antiphospholipid syndrome (TAPS) is characterized by venous, arterial, or
microvascular thrombosis. Patients with TAPS merit indefinite anticoagulation, and warfarin …

Background The cornerstone of thrombotic antiphospholipid syndrome (APS) patients'
management is to prevent recurrent thrombosis by long-term anticoagulation. Purpose of …

Antiphospholipid syndrome (APS) is an acquired autoimmune condition characterized by
thrombotic events, pregnancy morbidity, and laboratory evidence of antiphospholipid …

Objective The objective of this study was to clarify the efficacy and safety of factor Xa
inhibitors for antiphospholipid syndrome patients in real world utilization. Methods This is a …

Objectives Despite controversies, direct oral anticoagulants (DOACs) are increasingly used
in antiphospholipid syndrome (APS). We investigated the safety and efficacy of DOACs …

Anticoagulation with oral vitamin K antagonists (VKA) is the mainstay of the treatment of
venous and/or arterial thromboembolism in patients with antiphospholipid syndrome (APS) …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for secondary
prevention of venous thromboembolism (VTE) but their clinical efficacy and safety are not …

The direct oral anticoagulants (DOACs) are therapeutic alternatives to warfarin and other
vitamin K antagonists (VKAs), and constitute the standard of care for many indications. VKAs …